[company_age]8.0[/company_age][employees]501-1000 employees[/employees][funding]grant[/funding][description]Vir Biotechnology is a clinical-stage immunology company focused on developing transformative treatments for infectious diseases, viral-associated diseases, and immune targeting. The company leverages its deep immunology expertise and proprietary technology platforms to discover and develop novel monoclonal antibodies and T cell-based therapies. Vir's core strengths include its world-class monoclonal antibody platform, which is powered by artificial intelligence-led protein engineering capabilities, and its unique T cell-based viral vector platform. The company has a robust pipeline of product candidates in various stages of development, including two late-stage programs in chronic hepatitis delta and chronic hepatitis B. Vir is headquartered in San Francisco, California, and has operations in the United States and Europe.[/description][ps]Monoclonal antibodies, T cell-based therapies, infectious disease treatments, viral-associated disease treatments, immune targeting therapies[/ps]